← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $617B	1,974	+7	+0.4%	$185B
2	2 Pfizer PFE $169B	1,781	+44	+3%	$144B
3	3 Merck MRK $368B	1,603	+36	+2%	$124B
4	4 AbbVie ABBV $508B	1,422	-13	-0.9%	$56.6B
5	5 Bristol-Myers Squibb BMY $125B	1,329	+15	+1%	$61.1B
6	6 Gilead Sciences GILD $197B	1,188	+88	+8%	$116B
7	7 Amgen AMGN $238B	1,182	+27	+2%	$76B
8	8 Novartis NVS $287B	831	+15	+2%	$20.2B
9	9 GSK GSK $98.7B	713	+31	+5%	$14.4B
10	10 Regeneron Pharmaceuticals REGN $82.9B	453	+15	+3%	$22.1B
11	11 AstraZeneca AZN $260B	388	+8	+2%	$7.81B
12	12 Jazz Pharmaceuticals JAZZ $14B	318	+38	+14%	$7.03B
13	13 Myriad Genetics MYGN $419M	281	+10	+4%	$3.74B
14	14 Incyte INCY $23.1B	253	+22	+10%	$8.59B
15	SGEN 15 DELISTED Seagen Inc. Common Stock SGEN	210	+6	+3%	$5.81B
16	16 Opko Health OPK $1.18B	168	+12	+8%	$678M
17	17 Exelixis EXEL $15.6B	152	+21	+16%	$1.17B
18	18 DELISTED Exact Sciences EXAS	151	+20	+15%	$917M
19	19 DELISTED Immunogen Inc IMGN	142	+7	+5%	$1.14B
20	20 Puma Biotechnology PBYI $550M	138	+22	+19%	$2.62B
21	CLVS 21 DELISTED Clovis Oncology, Inc. CLVS	137	+25	+22%	$1.87B
22	22 Geron GERN $790M	133	-5	-4%	$172M
23	23 Halozyme HALO $13.7B	131	+12	+10%	$1.1B
24	24 DELISTED Assertio ASRT	123	+19	+18%	$634M
25	SPPI 25 DELISTED Spectrum Pharmaceuticals Inc SPPI	119	+4	+3%	$341M